Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-course versus conventional antibiotic therapy for gram-positive cocci infective endocarditis
2019-003358-10Phase 4Active
- Sponsor
- Carmen Olmos Blanco
- Start
- Nov 2019
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of benzylpenicillin, ceftriaxone, gentamicin, vancomycin, cloxacillin and 3 more in endocarditis (IE) (2 arms), sponsored by Carmen Olmos Blanco. Primary endpoint: Primary composite endpoint. Started Nov 2019; status: active.
02
Drugs
benzylpenicillinceftriaxonegentamicinvancomycincloxacillin
03
Conditions
endocarditis (IE)
Beyond the preview
Go deeper on 2019-003358-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003358-10.